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Abstract
Background: Many studies have reported beneficial effects from the application of near-infrared
(NIR) light photobiomodulation (PBM) to the body, and one group has reported beneficial effects
applying it to the brain in stroke patients. We have reported that the measurement of a patient's
left and right hemispheric emotional valence (HEV) may clarify data and guide lateralized
treatments. We sought to test whether a NIR treatment could 1. improve the psychological status
of patients, 2. show a relationship between immediate psychological improvements when HEV was
taken into account, and 3. show an increase in frontal pole regional cerebral blood flow (rCBF), and
4. be applied without side effects.
Methods: We gave 10 patients, (5 M/5 F) with major depression, including 9 with anxiety, 7 with
a past history of substance abuse (6 with an opiate abuse and 1 with an alcohol abuse history), and
3 with post traumatic stress disorder, a baseline standard diagnostic interview, a Hamilton
Depression Rating Scale (HAM-D), a Hamilton Anxiety Rating Scale (HAM-A), and a Positive and
Negative Affect Scale (PANAS). We then gave four 4-minute treatments in a random order: NIR
to left forehead at F3, to right forehead at F4, and placebo treatments (light off) at the same sites.
Immediately following each treatment we repeated the PANAS, and at 2-weeks and at 4-weeks
post treatment we repeated all 3 rating scales. During all treatments we recorded total hemoglobin
(cHb), as a measure of rCBF with a commercial NIR spectroscopy device over the left and the right
frontal poles of the brain.
Results: At 2-weeks post treatment 6 of 10 patients had a remission (a score ≤ 10) on the HAM-
D and 7 of 10 achieved this on the HAM-A. Patients experienced highly significant reductions in
both HAM-D and HAM-A scores following treatment, with the greatest reductions occurring at 2
weeks. Mean rCBF across hemispheres increased from 0.011 units in the off condition to 0.043
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units in the on condition, for a difference of 0.032 (95% CI: -0.016, 0.080) units, though this result
did not reach statistical significance. Immediately after treatment the PANAS improved to a
significantly greater extent with NIR "on" relative to NIR "off" when a hemisphere with more
positive HEV was treated than when one with more negative HEV was treated. We observed no
side effects.
Conclusion: This small feasibility study suggests that NIR-PBM may have utility for the treatment
of depression and other psychiatric disorders and that double blind randomized placebo-controlled
trials are indicated.
Trial registration: ClinicalTrials.gov Identifier: NCT00961454
Background
The National Comorbidity Survey [1] reported that 46%
of men and 58% of women were found to have suffered
in their lifetime at least a two week period in which they
experienced a persistent depressed mood. Major depres-
sion disorder (MDD) has a lifetime prevalence of about
16% [2], and it is estimated that by 2020, it will be the sec-
ond greatest contributor to the impairment of global
health [3]. A recent Australian survey reported that anxiety
disorders were the most common mental disorder with a
lifetime prevalence of 26% [4]. We present our findings
from an open study of a novel therapy for these prevalent,
deleterious conditions.
Photobiomodulation (PBM), also known as low level
laser therapy (LLLT), is the application of phototherapy,
often from a red or near-infrared laser, or from a non-
coherent light source, such as a light emitting diode
(LED). It been reported in over a thousand scientific pub-
lications to have therapeutic efficacy for a wide range of
disorders in humans without any observed harmful
effects. PBM has been demonstrated in cell culture to
increase mitochondrial respiration [5], increase ATP syn-
thesis [5-7], upregulate expression of reactive oxygen spe-
cies [8], modulate the expression of 111 genes in a cDNA
microarry study [9], and increase nerve cell proliferation
and migration [10]. PBM has been tested in animals to
facilitate wound healing [11], improve inflammatory
arthritis [12], promote the process of skeletal muscle
regeneration [13], and reduce infarct size in ischemic
heart muscle by 50 to 70% in an induced experimental
model in rats and dogs [14]. Transcranial PBM, using
near-infrared light which penetrates the scalp and skull,
can significantly reduce damage from experimentally
induced stroke in rats [10] and rabbits [15], can improve
the memory performance of middle aged mice [16], and
has been shown to reduce damage from acute stroke in
humans [17,18].
Several studies have suggested that depression is associ-
ated with abnormalities of frontal activation reflected in
abnormalities in frontal regional cerebral blood flow
(rCBF) [19-21]. PBM has induced increases in blood cir-
culation in the hands of patients with Raynaud's phenom-
enon [22,23], in skin flaps [24], and in healthy skin [25].
We sought to examine whether transcranial PBM might
alter pre-frontal rCBF as well as whether it can affect the
emotional status of patients with major depression with
anxiety. We see this small feasibility study as the first of a
series of experiments to explore eventually whether PBM
might be useful as a safe and effective treatment for psy-
chological disorders, and whether any observed improve-
ment might have a relationship with alterations in our
measurements of rCBF and hemispheric emotional
valence (HEV), the tendency for one cerebral hemisphere
(either left or right) to have, as a trait, a more positive psy-
chological disposition than the other.
Several treatments for depression, such as transcranial
magnetic stimulation [26], deep brain stimulation [27],
and electro-convulsive therapy [28], transcranial direct
current stimulation [29,30], apply energy to the brain and
have been effective in the treatment of major depressive
disorder (MDD) even though their mechanisms remain
uncertain. We believe this is the first study of transcranial
PBM, which also applies energy, as a treatment for any
psychological illness.
Methods
The protocol was approved by the Massachusetts General
Hospital (MGH) Institutional Review Board and was con-
ducted in accord with the principles of the Helsinki Dec-
laration. We studied 10 right-handed patients, described
in Tables 1, 2, and 3, who were recruited through adver-
tisements posted on the internet and at a substance abuse
clinic. Among those with a history of substance abuse, 6
had a past history of opiate dependence, and 1 had a past
history of alcohol dependence. Enrollment was made
without regard to gender or ethnicity. Inclusion criterion
allowed for patients receiving mental health care if they
had not altered their treatment during the month preced-
ing the study. At enrollment we asked that they try, but
not be required, to maintain their usual treatment until
the study's conclusion. All patients complied with thisBehavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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request, and no patient altered their usual treatment for
the duration of the 4-week study. We excluded patients
who were not right handed, not between the ages of 18
and 60 or failed to meet the structured clinical interview
for DSM-IV (SCID) criteria for MDD. We also excluded
any person with a past history of a psychotic disorder, a
substance abuse disorder that had been active within the
6 months prior to the study, a history of violent behavior,
a history of a past suicide gesture or attempt, a history of
current suicidal ideation, a history of a neurological con-
dition (e.g. epilepsy, traumatic brain injury, stroke), preg-
nancy, or a current acute or chronic medical condition.
We would have excluded any person whom we judged to
have an impaired decision-making capacity. Prior to
enrollment, we obtained informed consent according to
the existing policies at MGH. No patient, once enrolled,
failed to complete the study.
Instruments
Photobiomodulation with near infrared light
The treatment consisted of applying PBM in the form of a
light emitting diode (LED) array (Marubeni America
Corp, Santa Clara, CA) with a peak wavelength of 810 nm
with a full width half maximum of 40 nm, delivering an
irradiance of 250 mW/cm2 when applied at 4 mm from
the skin. The treatment consisted of exposure to the light
for 4 minutes (total delivered fluence per site of 60 J/cm2)
at each of 2 sites on the forehead that correspond to the
10-20 EEG sites, F3, and F4. Based on a penetration of
3.7% of the light to the dura, we calculated that 2.1 J/cm2
was delivered to each of the treated areas of the brain. The
level of light exposure at the skin was well below the irra-
diance allowed by the ANSI standard of 320 mW/cm2.
Based on that standard, we conclude that the level of light
exposure either to the skin (power density of 250 mW/
Table 1: Demographics: Age, gender, and SCID diagnosis
SCID Diagnosis
Subject # Age Gender Major Depression Anxiety Disorder PTSD Subs abuse history
13 8 M + +
22 6 F +
32 7 M + + + o p i a t e
4 42 M + + alcohol
54 0 F + + o p i a t e
63 4 M + + + o p i a t e
73 5 M + + o p i a t e
82 5 F + + + o p i a t e
94 6 F + +
10 38 F + + opiate
Mean ± SD 35 ± 7
N1 0 5  M 1 0 9 3 7
Table 2: Baseline measurements of outcome measures and hemispheric emotional valence.
Subject # Initial HAMD Initial HAMA Initial PANAS HEV value HEV category
1 19 16 11 -2 Right Negative
2 14 6 1.5 -1.5 Right Negative
3 26.5 19 11 -1 Right Negative
4 26 26 6 2 Left Negative
5 27 22 6.5 4 Left Negative
6 32 38 -5 11 Left Negative
7 11 16 3 26 Left Negative
8 33 48 -4 7 Left Negative
9 14 15 7 -1 Right Negative
10 36 24 2 -1 Right Negative
Mean ± SD 23.9 ± 8.8 23.0 ± 12.2 3.9 ± 5.5 4.35 ± 8.7
N 5R/5LBehavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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cm2 and total fluence of 60 J/cm2) and to the surface of the
brain (power density of 9.5 mW/cm2 and total fluence of
2.1 J/cm2) to each of the 2 treated areas of the forehead
poses no significant risk as discussed above. Subjects wore
protective eyewear even though the physician administer-
ing the PBM was careful to not shine the light in or near
the eyes. The output of our device is at least 5 times less
than the PhotoThera laser device (personal communica-
tion, Luis DeTaboada, PhotoThera Inc, Carlsbad, CA) that
was used without observed side-effects in stroke patients
[17], and was found in a study of the rat brains exposed to
light to cause no observable behavioral or cellular altera-
tions [31]. In the human stroke study, the patients' heads
were shaved and they were treated at 20 sites around the
entire head. Subjects were not shaved in the present study
as light was applied only to the forehead.
The rationale for the optical parameters were as follows:
The wavelength of 810-nm is optimum for light penetra-
tion of living tissue due to minimization of absorption by
all three major tissue chromophores, hemoglobin, mela-
nin and water. Moreover this wavelength has been shown
to be effectively absorbed by mitochondria that are
believed to be responsible for the biological effects of
photobiomodulation. The energy density (60 J/cm2) was
chosen with reference to other published studies report-
ing transcranial laser for stroke in humans and knowledge
about the optical properties of human tissue as discussed
in the text. The power density (250 mW/cm2) was chosen
to be safe and avoid heating of the skin.
Near Infra-red spectroscopy (NIRS) for the measurement of total oxy 
and deoxy-hemoglobin (cHb) in the left and right frontal poles
We measured cHb in left and right frontal poles by NIRS,
using an INVOS system (Somanetics, Troy, MI) http://
www.somanetics.com/invos-system, modified by Soman-
etics to provide cHb, which we believe to be our best
reflection of rCBF, in addition to the device's usual oxygen
saturation output. The Somanetics device is FDA
approved, is commercially available, and is used through-
out the world in hospital settings to monitor cerebral per-
fusion. It poses no harm or discomfort to subjects, yet is
convenient, and allows the subject to have relatively free
movement. This device can be used to monitor cHb in the
left and right frontal poles during PBM. Since our PBM
uses continuous wave emission, its light is not detected by
this NIRS device because it has a proprietary mechanism
for excluding continuous light so that ambient light does
not contaminate the device's pulsed photon emitter/
detector.
Affect measures
We evaluated the psychological state of patients with the
following instruments: Standard Clinical Diagnostic
Interview (SCID) [32], a Hamilton Depression Rating
Scale 21-item (HAM-D) [33], a Hamilton Anxiety Rating
Scale (HAM-A) [34], and a Positive and Negative Affect
Scale (PANAS) [35]. We searched for side effects of the
treatment with a form we constructed with both open-
ended questions and a physical and psychological symp-
tom check list.
Determination of hemispheric emotional valence
Lateral visual field stimulation (LVFS), a simple test, con-
sisting of blocking one visual field so that the patient is
looking exclusively out of the left or right lateral visual
field, at a photograph of a man or woman with an ambig-
uous emotional expression. The subject does so for one
minute then his affects are rated on an abbreviated PANAS
scale [36-39]. LVFS has been shown to alter hemispheric
activation by BOLD fMRI [40]. HEV determined by LVFS
has predicted in two independent studies the outcomes to
Table 3: Unaltered treatments before and during the study period.
Treatment
Subject # ssri or snri benzodiazepine buphenorphine methadone psychotherapy
1+
2+
3+ + + +
4+
5+ + + +




10 + + +
N8 4 5 1 4Behavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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a 2-week course of left-sided rTMS for depression [41,42].
We have suggested that HEV might be used to guide the
application lateral treatments to the brain and aid in the
evaluation of experimental data [39].
From the subjects' left and right-sided LVFS scores on the
PANAS we derived the patients' hemispheric emotional
valence (HEV). To determine the patient's baseline HEV,
before any treatments, we used the PANAS scores recorded
one minute after his or her looking out the right visual
field (RVF) and that recorded one minute after his looking
out the left visual field (LVF). We use this order of testing
for all patients. We used the difference between the
PANAS scores during the LVF - the RVF to determine the
HEV, for which we obtained an individual score. Since the
LVF is thought to relate to the right hemisphere, when
LVF-RVF was positive (right hemisphere had more posi-
tive affect), we assigned a left negative HEV, and when it
was negative, a right negative HEV.
Study design and procedures
Each of the 10 patients who met our criteria by a phone
interview came to our laboratory and gave written
informed consent according to approved protocol. Then
each was given a SCID, followed by a baseline HAM-D,
HAM-A, PANAS, and LVFS. Subjects were not drug tested,
but patients with a history of opiate abuse had been in a
stable treatment program for at lease 6-months, and each
was believed by their prescribing psychiatrist to have
abstained from illicit drugs for this period. Each subject
was then connected to our NIRS device by having 5 by 2.5
cm2 adhesive pads containing a photon emitter and detec-
tors attached to each side of the forehead immediately
over the eyebrows, as shown in Figure 1.
The NIRS device collected data continuously at 1-second
intervals throughout the study. Event marks indicated the
beginning and end of each baseline or treatment period.
Data were zeroed at the beginning of each period. A
researcher, blind to the treatments, administered the
PANAS scales at baseline and immediately after each of
the 4 treatments. A different researcher administered the
HAM-D and the HAM-A at baseline and at 2- and 4-weeks
post treatment. He was not blinded because all patients
received active treatments during the treatment day. In
random order, the patient was given the first of 4 interven-
tions, consisting of: A). NIR "on" for 4 minutes at F3 (of
the 10-20 EEG system), left forehead approximately over
the left dorsolateral prefrontal cortex, B). NIR "on" for 4
minutes at F4, C). NIR "off" with the NIR device held at
F3 for 4 minutes, as shown in Figure 1). The same as inter-
vention #C but at F4. Thus, we had two active treatments
and two placebo treatments. A cooling fan and heat sink
on the LED prevented detectable heat from reaching the
skin of the patient. Patients were asked if they could tell if
they had just received a treatment with the light on or off,
and all reported that they could not detect any differences
between the treatments. After all 4 interventions were
completed, the patients were asked about adverse physical
or psychological symptoms.
Two weeks and 4-weeks after the treatment day, each
patient was given a follow-up HAM-D, HAM-A, PANAS,
and the side-effects questionnaire.
Statistics
Our primary outcomes were changes from baseline in
HAM-D and HAM-A scores at 2 weeks and 4 weeks post-
treatment, and our secondary outcomes were change in
PANAS score at 2 weeks and 4 weeks post-treatment, dif-
ference in immediate after treatment in PANAS score
between NIR on and NIR off, and difference in rCBF
between NIR on and NIR off. We also tested for associa-
tions between treatment side that was matched or
unmatched with the hemisphere with a positive HEV and
PANAS changes immediately following treatment. Here
we used hierarchical linear models with treatment (NIR
on or off), side of treatment (F3 or F4), and their interac-
tion as predictors. HEV and its interaction with the side of
treatment were added to these models to test for an asso-
ciation between these factors and immediate treatment
benefit.
To test for changes in symptom ratings at 2 weeks and 4
weeks post-treatment, we used repeated measures linear
regression models with measurement time as a categorical
predictor and unstructured covariance between repeated
measurements. Paired comparisons between measure-
ment times were conducted in the presence of an overall
difference among mean symptom ratings at baseline, 2
Near infrared treatment Figure 1
Near infrared treatment. The NIR LED array is a few mil-
limeters from the skin beneath a heat sink and cooling fan at 
F3. Somanetics "SomaSensors" with NIR photon emitters and 
detectors are applied just above each eyebrow to measure 
left- and right-sided total hemoglobin.Behavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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weeks, and 4 weeks significant at the alpha = 0.05 level. To
facilitate the clinical interpretation of our findings and
comparison with other studies, we also report the number
of participants who were "improvers" (20% or more
decrease from baseline) and "responders" (50% or more
decrease from baseline) based on HAM-D and HAM-A
scores, the number who achieved "remission" (a score less
than 8 or 11) based on HAM-D and HAM-A scores, and
the mean ± standard deviation percentage change at 2
weeks and 4 weeks for the three clinical measures.
To test for associations between treatment and rCBF,
paired t-tests compared average rCBF across the left and
right hemispheres and rCBF within each hemisphere
between NIR on and NIR off. To test whether any treat-
ment effect differed between the left and right hemi-
spheres, an additional paired t-test compared mean
differences in rCBF between NIR on and NIR off between
the left and right hemispheres. We also considered hierar-
chical models for the association between treatment and
rCBF, but the data did not support their complexity.
Post-hoc tests for associations among hemispheric
valence, differences in rCBF, and two-week changes in
HAM-A and HAM-D scores were conducted using linear
regression with random intercepts for subjects when
appropriate. Both point changes and percentage changes
in HAM-D and HAM-A were considered as outcomes.
These models treated hemispheric valence as a quantita-
tive variable.
Statistical significance required two-tailed p-values less
than 0.05. A Bonferroni correction was applied to results
from the models for changes in HAM-D and HAM-A
scores with treatment to account for our choice of two pri-
mary clinical outcomes. Other results were not adjusted
for multiple comparisons. Statistical analyses were con-
ducted using R statistical software (version 2.9.2) and the
PROC MIXED routine for SAS statistical software (version
9.1.3, Cary, NC).
Results
Changes in rCBF in response to PBM with NIR, comparing 
the light off and light on conditions
Mean rCBf across hemispheres (left + right/2) increased
from 0.011 units in the sham condition to 0.043 units in
the treatment condition, for a difference of 0.032 (95%
CI: -0.016, 0.080) units, though this result did not reach
statistical significance (t9 = 1.52, p = 0.16). The increase
with treatment was 0.046 (95% CI: -0.004, 0.097; t9 =
2.07, p = 0.07) units in the left hemisphere and 0.018
(95% CI: -0.033, 0.069; t9 = 0.80, p = 0.44) units in the
right hemisphere, but the difference between hemispheres
was also not statistically significant (95% CI for differ-
ence: -0.01, 0.063; t9 = 1.83; p = 0.10). Figure 2 illustrates
these results.
Immediate affect responses to NIR or sham
There were no significant differences in PANAS scores
(immediately after treatment) between the NIR on and off
treatment conditions (t19 = -1.47, p = 0.16).
Although the PANAS scores were not significantly differ-
ent with the light on or off, we wondered whether apply-
ing NIR-PBM to a hemisphere with a positive HEV would
elicit more positive affect than when it was applied to a
hemisphere with a negative HEV. We found a statistically
significant interaction between NIR on treatment and
HEV supporting this hypothesis (t18 = 2.23, p = 0.04).
When NIR was applied to the HEV-positive hemisphere,
mean PANAS scores improved relative to when it was
applied to the HEV-negative hemisphere. The more
matched the treatment side and side of more positive
HEV, the greater the benefit of the infrared treatment con-
dition relative to the sham condition, where the most pro-
nounced difference between treatments was a
disadvantage of treatment relative to sham for unmatched
HEV.
Two week and 4-week psychological measures
All 3 of our post-treatment outcome measures showed
improvements at 2 weeks, which remained but were atten-
uated at 4 weeks. The improvement was statistically signif-
icant for HAM-D and HAM-A but not for PANAS.
Hamilton depression rating scale
Evaluating our first primary outcome measure, the HAM-
D, at 2 and 4-weeks post treatment (to both F3 and F4),
we found that there were significant changes in HAM-D
following treatment (F2,8 = 14.98, p = 0.004), with the
lowest symptom scores occurring 2 weeks post-treatment.
Mean HAM-D decreased significantly by 13.20 (95% CI:
6.46-19.94) points at 2 weeks (t9 = -5.26, p = 0.001) and
6.50 (95% CI: 0.28-12.72) points at 4 weeks (t9 = -2.81, p
= 0.04). The increases in HAM-D between 2 weeks and 4
weeks were also significant (t9 = 4.45, p = 0.003).
Mean percentage reductions in HAM-D scores were 54.3%
± 26.1 at 2 weeks post-treatment and 23.0% ± 27.1 at 4-
weeks post-treatment. At 2-weeks all 10 patients were
"improvers," defined in the literature as those patients
who respond to an intervention for depression with at
least a 20% reduction in HAM-D; 4 out of 10 patients
were "responders" (>50% reduction in HAM-D), among
whom there was a reduction of 82.8% ± 5.8. Four out of
the 10 patients achieved "remission," (HAM-D <8). Some
authors define "remission" as a score ≤ 10 [43], and using
that standard, 6 out of 10 achieved "remission." At 4
weeks, we observed that 5 out of 10 patients were stillBehavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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"improvers;" 2 were still "responders," and no patient still
achieved "remission" at <8, but one achieved "remission"
at the ≤ 10 criterion. Figure 3 shows the HAM-D results for
the 10 individual patients at 2-weeks post-treatment. At
that point, 4 of the 5 males, but no females achieved a
remission at <8.
Hamilton anxiety rating scale
Evaluating our second primary outcome measure, the
HAM-A, at 2- and 4-weeks post-treatment, we found that
there were significant changes in HAM-A following treat-
ment (F2,8 = 11.70, p = 0.008), with the lowest symptom
scores occurring 2-weeks post-treatment. Mean HAM-A
decreased significantly by 14.90 (95% CI: 6.77-23.03)
points at 2 weeks (t9 = -4.92, p = 0.002) and 9.00 (95% CI
2.66-15.34) points at 4 weeks (t9 = -3.81, p = 0.008). The
increases in HAM-A between 2 weeks and 4 weeks were
also significant (t9 = 4.35, p = 0.004).
Mean percentage reductions in HAM-A scores were 63.1%
± 23.0 at 2 weeks post-treatment and 36.6% ± 23.0 at 4-
weeks post-treatment. At 2 weeks, all 10 patients were
"improvers;" 7 out of 10 were "responders" (>50% reduc-
tion in HAM-A), among whom there was a reduction of
74.7% ± 16.2. Five of the 10 patients achieved "remis-
sion" at HAM-A <8, and 7 of the 10 achieved it at HAM-A
≤ 10. At 4-weeks, 9 of the 10 were still "improvers," 3 of
the 10 were still "responders," and 2 of the 10 still
achieved "remission" at HAM-A <8, and 6 of the 10
achieved a remission at HAM-A ≤ 10. Figure 4 shows the
HAM-A results for the 10 individual patients at 2-weeks
post-treatment. At that point, 4 of the 5 males achieved a
remission at <8, as did 1 of 5 females. Table 4. summa-
rizes the HAM-D and the HAM-A outcomes at 2- and 4-
weeks post-treatment.
PANAS scale
The mean initial PANAS was 3.9 ± 5.5; the 2-week mean
PANAS was 8.8 ± 6.6; and the 4-week mean PANAS was
6.8 ± 4.9. Unlike the HAM-D and HAM-A, an increase in
the PANAS score represents an improvement. All 3 of our
outcome measures showed an improvement at 2 weeks,
which decreased by 4 weeks but remained better than
baseline. Mean PANAS increased by 4.90 (95% CI: 0.49-
9.31) points at week 2 relative to baseline and 2.85 (95%
CI: -1.28-6.98) points at week 4 relative to baseline. These
changes in PANAS scores at 2- and 4-weeks post-treatment
did not achieve statistical significance (F2,8 = 3.21, p =
0.09). We observed an improvement in the PANAS scale
from baseline to 2 weeks of 122% ± 183 and 54% ± 133
at 4 weeks.
Predictors of 2-week outcomes
When percentage change in HAM-A (but not HAM-D) at
2 weeks was considered, there was a significant associa-
tion between the left minus the right frontal rCBF and the
baseline HEV score and the change in HAM-A such that a
greater right positive HEV was associated with a greater
rCBF in the right frontal pole and a greater left positive
HEV was associated with a greater rCBF in the left frontal
pole. This greater rCBF in the direction of positive hemi-
spheric valence was associated with greater reductions in
HAM-A scores (t6 = 3.26, p = 0.02), though there was no
such association with differences in differential blood
flow between the NIR on and NIR off conditions (t6 =
1.67, p = 0.15). When the differences between baseline
and 2-week values for HAM-D or HAM-A were used,
instead of the percent change, as the outcome measures,
then there were no significant associations between the
direction of rCBF and HEV (t6 = 0.40, p = 0.70 HAM-D; t6
= 0.12, p = 0.91 HAM-A)
Safety
No adverse events or side effects were found after detailed
questioning of the patients immediately after the initial
visit to the laboratory and at 2 and 4 weeks post-treat-
ment.
Pre-frontal blood flow, "NIR on" versus "placebo" Figure 2
Pre-frontal blood flow, "NIR on" versus "placebo". A 
comparison of the mean left-, right-sided, and left + right 
pre-frontal total hemoglobin (cHb) measurements (arbitrary, 
relative units) recorded during the two 4-minuted NIR treat-
ments (F3 and F4), light on conditions, and during the two 4-
minute placebo (LED off) conditions (F3 and F4). cHb is an 
index of regional cerebral blood flow (rCBF). Mean rCBf 
across hemispheres (left + right/2) increased from 0.011 
units in the sham condition to 0.043 units in the treatment 
condition, for a difference of 0.032 (95% CI: -0.016, 0.080) 
units, though this result did not reach statistical significance 
(t9 = 1.52, p = 0.16). The increase with treatment was 0.046 
(95% CI: -0.004, 0.097; t9 = 2.07, p = 0.07) units in the left 
hemisphere and 0.018 (95% CI: -0.033, 0.069; t9 = 0.80, p = 
0.44) units in the right hemisphere, but the difference 
between hemispheres was also not statistically significant 
(95% CI for difference: -0.01, 0.063; t9 = 1.83; p = 0.10). 
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Initial, 2-week, and 4-week HAM-D scores Figure 3
Initial, 2-week, and 4-week HAM-D scores. The individual patient's Hamilton Depression Rating Scores at Baseline, 2-
weeks, and at 4-weeks. A high score suggests more depression. Fifteen or above is suggestive of a clinical depression and below 
8 is suggestive of a remission. The legend numbers correspond to the patient numbers. The mean scores are indicated.
Table 4: Patient outcomes at 2- and at 4-weeks post-treatment on the HAM-D and the HAM-A. Data are means ± sd
Measure Initial minus post-
treatment
% Decrease % Decrease >20% % Decrease >50% Score <8 Score ≤ 10
Improvers Responders Remission Remission
2 weeks post-
treatment
HAM-D 13.2 ± 7.9 54.3% ± 26.1 100% 40% 40% 60%
HAM-A 14.9 ± 9.6 63.1% ± 23.0 100% 70% 50% 70%
4 weeks post-
treatment
HAM-D 6.5 ± 7.3 23.0% ± 27.1 50% 20% 0.0 10%
HAM-A 9.0 ± 7.5 36.6% ± 23.0 90% 30% 20% 60%
Statistical tests are presented in the text.Behavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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Discussion
Many studies have reported beneficial effects from the
application of red and NIR light to the body [44-46], and
one group [17,18] reported beneficial effects applying
transcranial NIR to the brain in stroke patients. We
embarked on this study to see if the psychological status
of patients with depression might benefit from the appli-
cation of NIR light to the head. Although we recruited for
patients with depression, we found that 9 of those who
responded also manifest an anxiety disorder by SCID,
including 3 who met criteria for both generalized anxiety
disorder and PTSD. Seven of these patients had also a past
history of opiate abuse, 6 treated with buprenorphine and
1 with methadone. We intended this as a small pilot study
for an initial evaluation of our treatment's safety (imme-
diately and over 4-weeks) and to look for indications that
it might have some efficacy immediately after each treat-
ment, and/or at 2 and at 4-weeks post-treatment. We had
4 treatment conditions, NIR at F3 and at F4, and "no
light" with the mushroom fan on at F3 and F4, as placebo
conditions. We measured also rCBF by NIRS to a depth of
at least 1 cm at the left and right frontal poles of the brain
to see if the NIR treatment might have a definite physio-
logical effect, and, if so, to see if the blood flow measure-
ments might shed any information about the treatment's
mechanism of action. We measured the patients' baseline
HEVs because our prior studies determined that the meas-
urement might be useful in data analysis and in guiding
treatment [39,41,42].
Our results showed that with one 4-minute NIR treatment
on each side of the head there were marked benefits in
both of our primary outcome measures, the HAM-D and
the HAM-A. We observed the greatest benefit at 2-weeks
post-treatment for both measures. At 4 weeks both
showed a statistically significant improvement over base-
line but a significant decline from 2-week levels. These
Initial, 2-week, and 4-week HAM-A scores Figure 4
Initial, 2-week, and 4-week HAM-A scores. The individual patient's Hamilton Anxiety Rating Scores at Baseline, 2-weeks, 
and at 4-weeks. A high score suggests more anxiety. Fifteen or above is suggestive of a clinical anxiety disorder and below 8 is 
suggestive of a remission. The legend numbers correspond to the patient numbers. The mean scores are indicated.Behavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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results should be interpreted with caution since this was
not a placebo-controlled trial.
The HAM-D and HAM-A are not suited for measuring
immediate effects, but are used to measure outcomes over
a longer period. The PANAS was most useful for evaluat-
ing immediate post-treatment effects, but was also used at
2 and 4 weeks. There were no statistically significant asso-
ciations between treatment and PANAS scores, either at
the time of treatment or during the four-week follow-up
period.
The size of our sample was too small to represent the
larger patient populations, but still within this popula-
tion, a single, brief treatment with transcranial NIR light
had effects that seem to compare well with other modali-
ties. For example in a previous study we reported [42],
using transcranial magnetic stimulation, to treat 37 refrac-
tory depressed patients over two weeks, and used the same
21-item HAM-D as in the present study, and found at 2-
weeks following the completion of the treatment a mean
percent decrease in HAM-D of 29.4% ± 26.1. In the
present study, we found a mean percent decrease in the
HAM-D of 54.3% ± 26.1 at 2-weeks post-treatment. The
rTMS study had a larger population (N = 37), and the
mean baseline HAM-D was 29.6 ± 5.6, which was higher
than that for the population in this study (23.8 ± 8.8).
Therefore, the studies cannot be directly compared, but it
is unusual for to find two studies with the identical out-
come measures applied at identical times. In a recent
rTMS study by Stern et al [43] in which they compared
outcomes using different stimulation parameters, the best
group had a remission (≤ 10) rate of 40% at 2-weeks post-
treatment; in the present study there was a remission rate
of 60% at 2-weeks.
Gershon et al [47] reviewed the efficacy of rTMS and
found a wide range of " % responders" (decrease % in
HAM-D ≥ 50%) from 10 to 49% among 5 sham control-
led studies. In all of these studies the active treatment was
far superior to the sham, which ranged from a 0% to a
25% response rate. Loo et al [48] reported in a recent
rTMS study, using twice daily left-sided high frequency
rTMS, a decrease in HAM-D of 38.5% immediately after a
2-week sham controlled study, compared to 54.3% in our
study 2-weeks after treatment.
Some studies have compared rTMS with electroconvulsive
therapy (ECT) [49-51], and found them generally to have
a similar efficacy in severe depression. For instance, Jani-
cak et al [50] compared up to 20 rTMS treatments with 3
to 12 ECT treatments and reported at the end of treatment
the rTMS group had a "remission" rate (<8) of 46% com-
pared with 56% for the ECT group. The authors did not
report 2-week post-treatment results. Our 2-week post-
treatment HAM-D scores indicated that 40% had achieved
"remission" (< 8).
In a recent study comparing the efficacy of 6 right-sided
ECT treatments with 6 bilateral over 3 weeks, Eschweiler
et al. [52] found that both groups had a 37% decrease in
HAM-D at the end of treatment. Each group had 26%
"responders" (≥ 50%) at the end of treatment. Again, our
group at 2-weeks post-treatment had a mean decrease in
HAM-D of 54.3% with 40% "responders" (≥ 50%).
In a recent study, Tadi et al [53] compared the outcomes
in HAM-D from baseline to 10 weeks for 223 patients
with depression randomized between 4 treatment groups:
sertraline, placebo pill, cognitive-behavioral therapy
(CBT), and guided self-help group (GSG). At 10-weeks,
the completion of the treatments, 44% of the sertraline
group responded (HAM-D % decrease ≥ 50%), compared
with 19% for the placebo group, 20% for the CBT group,
and 19% for the GSG group. By the second week 49% of
the sertraline group, 40% of the placebo group, 39% of
the CBT group, and 35% of the GSG group showed
improvement defined as a decrease in HAM-D of ≥ 20%.
In our study at 2-weeks post-treatment 100% showed
improvement (decrease in HAM-D ≥ 20%).
Katz et al [54] reported HAM-D outcomes for 70
depressed patients (baseline HAM-D = 23.5) randomly
divided between 3 treatment groups: desipramine, parox-
etine, and placebo. At 2-weeks the desipramine group had
a mean % decrease in HAM-D of 45%, the paroxetine
group, 24%, and the placebo group, 36%.
Bech et al [55] performed a meta-analysis of 16 US trials
involving depressed patients comparing fluoxetine with
either tricyclic antidepressants or with placebo in trials of
at least 6-weeks. The authors reported that among the
1914 patients intended to treat with fluoxetine, 38.5%
were responders (HAM-D reduction ≥ 50%), while among
the 686 TCA treated patients this measure was 35.5%, and
among the 847 placebo treated patients the measure was
24.2%.
In regard to anxiety, Leichsenring et al [56] found that 29
patients with a generalized anxiety disorder (GAD) treated
with CBT for 30 weeks achieved a 50.7% reduction on the
HAM-A at the end of treatment, and that 28 patients
treated with short-term psychodynamic psychotherapy
over the same time period achieved a 42.8% reduction. In
our study at 2-weeks post-treatment, our patients achieved
a reduction in HAM-A of 63.1%. Moreover, Montgomery
et al [57] reported pooled data from 6 double-blinded,
placebo-controlled, 4 to 6-week trials for patients with
GAD treated with a benzodiazepine (either alprazolam or
lorazepam), with pregabalin (PGB), or with placebo. TheBehavioral and Brain Functions 2009, 5:46 http://www.behavioralandbrainfunctions.com/content/5/1/46
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benzodiazepine group had a mean decrease in HAM-A
from baseline to the end of treatment of -11.0 points, the
PGB group had a decrease of -11.2, and the placebo
group, -8.3. In our study, we found a decrease in HAM-A
from baseline to 2-weeks post-treatment of 14.9 points.
Even though our 2-week results compare well with the
other reported treatments cited above, the 2 and 4-week
outcomes were unblinded, and did not have a placebo
control. Further, comparisons between treatments need to
be made with a single study and those results replicated.
Some of our secondary experiments showed results in
support of our initial hypotheses. For example, there was
greater rCBF during NIR on versus off, although this dif-
ference did not achieve statistical significance. NIR on was
more successful relative to NIR off when treatment was
applied to a hemisphere with more positive HEV.
An increase in rCBF with NIR is consistent with an effect
of NIR treatment on the brain. This effect on the brain
(whatever its complex nature) likely relates to the altera-
tions in affect. Together with our result that immediate
psychological benefit of infrared treatment was associated
with positive HEV, that the 2-week HAM-A outcomes
related to the HEV value and left - right rCBF is consistent
with the hypothesis we presented at length in a previous
publication [39], stating that the right hemisphere is often
associated (unexpectedly) with a positive HEV and that
knowing a patient's HEV can enlighten data reduction and
possibly guide treatment. We did not use HEV to guide
therapy in this study, but we think that future studies
should consider this possibility. In two other previous,
independent publications we reported that HEV by LVFS
could predict positive responses to left-sided rTMS
[41,42]. While promising, the result of an association
with 2-week changes in HAM-A should be interpreted
with caution since it was based on a post-hoc analysis, was
sensitive to our quantification of change in HAM-A (per-
cent vs. points change), and did not hold for HAM-D.
Because this is the first trial applying NIR to the brain, we
wanted to be extremely vigilant for negative side effects.
We found none, during or after the procedure. During the
treatments we turned off the fluorescent lights to prevent
interference with our NIRS data and the fan created a
drone and light breeze, all of which seemed to relax the
patients, although we did not formally measure this. Cer-
tainly, no patient complained of headaches or any other
physical discomfort. No patient dropped out of the study
and all continued through the 4-week follow-up. Six
patients spontaneously reported feeling much improved
at 2-weeks and attributed that improvement (rightly or
wrongly) to the treatment. The other 4 patients did not
feel any effect, positive or negative, from the treatment,
including one man who had an 85% improvement on his
HAM-D and a 68% improvement on his HAM-A at 2-
weeks. Thus, we observed the treatment to be comforta-
ble, pleasant, easy to apply, and safe.
The mechanism by which NIR-PBM has improved mood
is not understood. PBM is known to improve blood flow
in skin (as measured by laser Doppler) [58]. The fact that
HEV may play a role in the response suggests that positive
neural circuits might somehow be stimulated by NIR light
or negative neural circuits may be inhibited. NIR is known
to increase mitochondrial ATP and nerve growth factors.
We feel that our outcome findings must be replicated in
double blind, randomized, placebo-controlled prospec-
tive outcome studies with large numbers and various pop-
ulations. The method of treatment should also be studied
to attempt to optimize the results. Some possibilities are
to use pulsed light, try different anatomical locations, dif-
ferent treatment schedules (daily, weekly, biweekly, etc)
as well as different light wavelengths and total energy den-
sities. We would like to study also whether HEV should
guide treatment. Lastly, this treatment might benefit from
a possible synergy with other treatments such as psycho-
therapy and psychotropic medications. All the subjects in
this study remained on their usual treatment and no one
altered their usual treatment during this study. If further
study confirms our results or improves upon them, then
an intense search for the mechanism of action will be
highly desirable and might lead to greater knowledge of
mind-brain interactions, the psychophysiology of mental
states, including the effects of trauma, and of treatment
benefits.
Conclusion
We gave one 8-minute treatment with NIR-PBM to 10
patients with major depression, including 7 with a history
of substance abuse (6 with a past history of opiate abuse
and one with a past history of alcoholism), and 9 with an
anxiety disorder, including 3 with PTSD. We found signif-
icant reductions in both mean HAM-D and HAM-A rating
at 2 and 4 weeks following treatment. At 2-weeks post
treatment 6 of 10 of patients had a remission (a score ≤
10) on the HAM-D and 7 of 10 on the HAM-A. We
observed no side effects. This small feasibility study sug-
gests that follow-up double blind randomized placebo-
controlled trials of NIR-PBM for the treatment of psycho-
logical disorders are indicated.
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